Oncolytics Biotech (oncy) Misses Q3 EPS by 25c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. QGEN
5. QS
6. BFH
7. BRO
8. SAP
9. RCUS
10. LMT

Go back to Oncolytics Biotech (oncy) Misses Q3 EPS by 25c

Oncolytics Biotech® Inc. Announces 2015 Third Quarter Results

November 5, 2015 6:30 AM EST

CALGARY, Nov. 5, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX:ONC, OTCQX: ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the third quarter ended September 30, 2015.

"During the quarter, we announced exciting initial clinical data from our multiple myeloma study showing statistically significant increases in the production of caspase-3 and upregulation of PD-L1 along with an early objective response rate of 100%," said Dr. Brad Thompson, President and CEO of Oncolytics. "We also announced one and two-year survival data versus historical controls from our pancreatic (REO 017)... More